Lymphokine activated effector cells for antibody-dependent cellu

Details Lymphokine activated effector cells for antibody-dependent cellu Lymphokine activated effector cells for antibody-dependent cellu

1991-12-13

1994-05-03

Hill, Jr., Robert J.

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

424 851, 424 852, 424 854, 424 858, 435 704, 435 705, 4352402, A61K 4505, A61K 39395, A61K 3766, A61K 3514

Patent

active

053086260

ABSTRACT:
This invention relates to processes and compositions for the immunotherapeutic treatment of cancer and non-malignant tumors. More particularly, this invention relates to processes and compositions for enhancing the body's immune response by increasing the cytotoxic activity of cells which mediate antibody dependent cellular cytotoxicity. Cells which are characterized by increased cytotoxic activity, as a result of the process of this invention, are useful in methods and compositions for the treatment of various types of cancer and non-malignant tumors.

REFERENCES:
patent: 4596774 (1987-06-01), Chang et al.
patent: 4690915 (1987-09-01), Rosenberg
patent: 4844893 (1989-07-01), Honsik et al.
Moretta, L., et al. (1981) J. Exp. Med. 154:569-74.
Fabricius, H.-A. et al. (1979) Immunobiol. 156:364-71.
Fuson, E. W. et al. (1978) J. Immunol. 120:1726-32.
Guyre, P. M. et al. (1983) J. Clin. Invest. 72:393-97.
Fridman, W. H. et al (1980) J. Immunol. 124:2436-41.
Jones et al. (1980) J. Immunol. 125:926-33.
Journal Biological Response Modifier, 9, 1990, pp. 15-23 Riccardi et al.
Nio et al, Anticancer Research 10, 1990, pp. 441-446.
Plate et al, Annals of the New York Academy of Science vol. 532, 1988, pp. 149-157.
Issekutz, J Immunol 144, 1990, pp. 2140-2146.
J. W. Greiner, et al, "Enhanced Expression of Surface Tumor-associated Antigens on Human Breast and Colon Tumor Cells after Recombinant Human Leukocyte .alpha.-Interferon Treatment," Cancer Res., vol. 44, (1984), pp. 3208-3214.
K. Imai, et al, "Differential Effect of Interferon on the Expression of Tumor-associated Antigens and Histocompatibility Antigens on Human Melanoma Cells: Relationship to Susceptibility to Immune Lysis Mediated by Monoclonal Antibodies," J. Immunol., vol. 127 (1981), pp. 505-509.
E. B. Walker, et al, "Murine Gamma Interferon Activates the Release of a Macrophage-derived Ia-Inducing Factor that Transfers Ia Inductive Capacity," J. Exp. Med., vol. 159 (1984), pp. 1532-1547.
B. L. Cohen, et al, "Suppression by Alpha-Fetoprotein of Murine Natural Killer Cell Activity Stimulated in Vitro and in Vivo by Interferon and Interleukin 2," Scand. J. Immunol., vol. 23 (1986), pp. 211-223; Chemical Abstract, vol. 104 (1986).
M. G. Baines, et al, "Involvement of Transferrin and Transferrin Receptors in Human Natural Killer Effector:Target Interaction," Immunol. Lett. 7(1), pp. 51-55 (1983), Abst. No. 211018y (Chem. Abst., vol. 99, issued 1983.
E. Diener, et al, "Specific Immunosuppression by Immunotoxins Containing Daunomycin," Science, vol. 231 (1986), pp. 148-150.
J. C. Roder, et al, "Target-Effector Interaction in the Human and Murine Natural Killer System," J. Exp. Med., vol. 150 (1979), pp. 471-481.
J. A. Werkmeister, et al, "Identification of a Structure on Human Melanoma Cells Recognized by CTL Exhibiting Anomalous Killer Cell Function," J. Immunol., vol. 135 (1985), pp. 689-695.
D. Wallach, et al, "Preferential Effect of y Interferon on the Synthesis of HLA Antigens and their mRNAs in Human Cells," Nature, vol. 299 (1982), pp. 833-836.
Lanier et al J Immunol 134, 1985, pp. 794-801.
Shaw et al, Cell. Immunol 1985, 91, pp. 193-200.
Phillips et al J Exp Medicine 1985, pp. 1461-1482 vol. 161.
Nair et al J Immunol 129, 1982, pp. 2511-2518.
Burns et al, J Immunol 133, 1984, pp. 1656-1663.
Cheever et al; J Biol Response Modifier 3, 1984, pp. 113-127.
Kedou et al, J Biol Response Modifier 3, 1984, pp. 517-526.
Merluzzi et al, J Biol Response Modifier 3, 1984, pp. 468-474.
Guimar et al J Exp Med 155, 1982, pp. 1823-1841.
Lotz et al Carrier Res 41, 1981, pp. 4420-4425.
Lotz et al J Biol Response Modifier 3, 1984, pp. 475-482.
Imai et al Scand. J Immunol 14, 1981, pp. 369-377.
Schultz et al PNAS 80, 1983, pp. 5407-5411.
Gore et al, B J Cancer 48, 1983, pp. 877-879.
Simone et al, Nature 297, 1982, pp. 234-236.
Jones et al J Immunol, vol. 125, 1980, pp. 926-933.
Kosugi et al, Jpn J Cancer Chemother. 11(8) 1984, pp. 1527-1535.
Bakais et al, J Clin Lab Immunol 1984, pp. 77-84, vol. 15.
Fukui et al, Proc 14th Internal Congress of Chemotherapy vol. 2 1985 pp. 971-972.
Mule et al, Science 225; 1984, pp. 1487-1489.
Hefeneider et al, J Immunol 130(1) 1983, pp. 222-227.
Chang et al, J. Biol Resp Modifiers3, 1984, pp. 561-572.

Affiliated with

Also associated with

Rating

Lymphokine activated effector cells for antibody-dependent cellu does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lymphokine activated effector cells for antibody-dependent cellu, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lymphokine activated effector cells for antibody-dependent cellu will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2113348